| Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic … MH Forouzanfar, A Afshin, LT Alexander, HR Anderson, ZA Bhutta, ... The lancet 388 (10053), 1659-1724, 2016 | 7971 | 2016 |
| Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global … H Wang, M Naghavi, C Allen, RM Barber, ZA Bhutta, A Carter, DC Casey, ... The lancet 388 (10053), 1459-1544, 2016 | 5292 | 2016 |
| Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 … HH Kyu, D Abate, KH Abate, SM Abay, C Abbafati, N Abbasi, ... The Lancet 392 (10159), 1859-1922, 2018 | 3932 | 2018 |
| Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying … CJL Murray, RM Barber, KJ Foreman, AA Ozgoren, F Abd-Allah, SF Abera, ... The Lancet 386 (10009), 2145-2191, 2015 | 3382* | 2015 |
| Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 NJ Kassebaum, RM Barber, ZA Bhutta, L Dandona, PW Gething, SI Hay, ... The lancet 388 (10053), 1775-1812, 2016 | 1209 | 2016 |
| Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors A Duenas-Gonzalez, M Candelaria, C Perez-Plascencia, ... Cancer treatment reviews 34 (3), 206-222, 2008 | 427 | 2008 |
| Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects P Vila, MC Hernandez, MF Lopez-Fernandez, J Batlle Thrombosis and haemostasis 72 (08), 209-213, 1994 | 347 | 1994 |
| Epigenetics of cervical cancer. An overview and therapeutic perspectives A Dueñas-González, M Lizano, M Candelaria, L Cetina, C Arce, ... Molecular cancer 4, 1-24, 2005 | 302 | 2005 |
| A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors M Candelaria, D Gallardo-Rincón, C Arce, L Cetina, JL Aguilar-Ponce, ... Annals of Oncology 18 (9), 1529-1538, 2007 | 296 | 2007 |
| Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer A Serrano-Olvera, A Dueñas-González, D Gallardo-Rincón, M Candelaria, ... Cancer treatment reviews 32 (3), 180-190, 2006 | 178 | 2006 |
| A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer C Arce, C Pérez-Plasencia, A González-Fierro, E de la Cruz-Hernández, ... PloS one 1 (1), e98, 2006 | 171 | 2006 |
| Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study A Chavez-Blanco, B Segura-Pacheco, E Perez-Cardenas, L Taja-Chayeb, ... Molecular cancer 4, 1-9, 2005 | 170 | 2005 |
| Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines A Chavez-Blanco, C Perez-Plasencia, E Perez-Cardenas, ... Cancer cell international 6, 1-9, 2006 | 164 | 2006 |
| A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results J Coronel, L Cetina, I Pacheco, C Trejo-Becerril, A González-Fierro, ... Medical oncology 28, 540-546, 2011 | 161 | 2011 |
| Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours JT Hartmann, M Candelaria, MA Kuczyk, HJ Schmoll, C Bokemeyer European Journal of Cancer 33 (6), 843-847, 1997 | 131 | 1997 |
| Radiosensitizers in cervical cancer. Cisplatin and beyond M Candelaria, A Garcia-Arias, L Cetina, A Dueñas-Gonzalez Radiation oncology 1, 1-17, 2006 | 130 | 2006 |
| Hydralazine target: from blood vessels to the epigenome C Arce, B Segura-Pacheco, E Perez-Cardenas, L Taja-Chayeb, ... Journal of translational medicine 4, 1-16, 2006 | 122 | 2006 |
| Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors JT Hartmann, HJ Schmoll, MA Kuczyk, M Candelaria, C Bokemeyer Annals of oncology 8 (6), 531-538, 1997 | 118 | 1997 |
| The prince and the pauper. A tale of anticancer targeted agents A Dueñas-González, P García-López, LA Herrera, JL Medina-Franco, ... Molecular cancer 7, 1-33, 2008 | 109 | 2008 |
| Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopy N Barahmani, A Lopez, D Babu, M Hernandez, SE Donley, M Duvic Clinical and experimental dermatology 35 (4), 409-416, 2010 | 100 | 2010 |
